Khiron Expands Product Offering in UK and Increases Patient Access Following successful medical cannabis launch in Germany, Khiron 1/14, a high CBD flower is expected to be available in Q2/21 for UK patients Khiron plans to introduce additional cannabis-based medical products with its registered strains, recently exported from Colombia to Europe Supply chain improvements will increase availability of medical cannabis for patients in the United Kingdom TORONTO, April 7, 2021 /PRNewswire/ -- Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to provide an operational update with regards to its supply of EU-GMP medical cannabis products to the UK. To help alleviate bottlenecks and stock outs, the Company has established an offshore inventory of dried flower, for the express purpose of serving UK patients.